Health data research in the UK is rapidly evolving, with new capabilities emerging through the rise of hybrid engagement and the accelerated adoption of digital technologies.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.